Surgery Partners Stock Price and Value Analysis

Should you buy Surgery Partners stock? (NasdaqGS:SGRY). Let's see how it does in our automated value investing analysis system.

SGRY Free Cash Flow Trend

Free Cash Flow trendline for SGRY
Free Cash Flow trendline for Surgery Partners

Hmm, we can't give any reliable projection for Surgery Partners's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This company has wild ups and downs.
  • This company is less known than others.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the SGRY Numbers

SGRY Price
(Surgery Partners stock price per share)
$5.76
PE Ratio versus Sector 100% lower than other Healthcare stocks
PE Ratio versus Industry 0% lower than other Medical Care stocks
Free Cash Flow Jitter 80%

Is Surgery Partners Stock on Sale?

Based on our analysis, we believe that you should not buy Surgery Partners right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy SGRY Stock?

Does Surgery Partners have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.